Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
Key data includes ASCO oral presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN
Source: finanznachrichten.de